COMPANY

Corcept Therapeutics

HQ: Redwood City, CA source · corcept.com ↗

FDA-approved therapeutic company Clinical Phase 3

80 open jobs · last seen Oct 23, 2026 · 52 sources

Location: Redwood City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Cushing Syndrome Nonalcoholic Steatohepatitis Hypercortisolism Metabolic Dysfunction-Associated Steatohepatitis Metabolic Dysfunction-Associated Steatotic Liver Disease Non-alcoholic Fatty Liver Disease Peritoneal Neoplasms Hepatic Impairment Non-alcoholic Steatohepatitis Antipsychotic-induced Weight Gain Cushing's Syndrome Antipsychotic Induced Weight Gain Ovarian Neoplasm Fallopian Tube Neoplasms Adenocarcinoma Pancreatic Ductal Carcinoma Amyotrophic Lateral Sclerosis Ovarian Cancer Fallopian Tube Cancer Endometrial Cancer Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis Metastatic Castration-Resistant Prostate Cancer Resistant Hypertension Recurrent Ovarian Cancer Recurrent Fallopian Tube Carcinoma Recurrent Primary Peritoneal Carcinoma Type 2 Diabetes Mellitus Adrenocortical Carcinoma Metastatic Pancreatic Ductal Adenocarcinoma relacorilant Miricorilant CORT125134 Dazucorilant CORT125236

80Open jobs 73Trials (company is sponsor)1FDA records (2 yrs)

Hiring

Title	Location (from posting)	Employer posted	First seen
Senior Manager, SOX	Redwood City, California, United States	Oct 19, 2026	Oct 20, 2026
Manager, Internal Events and Community	Redwood City, California, United States	Oct 16, 2026	Oct 17, 2026
Associate I, Regulatory Affairs	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026
Associate Director, Regulatory Affairs	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026
Senior Manager, Development Systems	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026

See all 80 jobs

Trial and FDA signals

Drug approval + hiring FDA novel approval for LIFYORLI (COPACKAGED) (NDA 220641, Mar 25, 2026); since then posted 37 manufacturing/quality or commercial roles. FDA NDA 220641 (Mar 25, 2026)
Evidence (1 event)
- Mar 25, 2026 · FDA NDA 220641
  openFDA drugsfda: application_number=NDA220641; sponsor_name='CORCEPT THERAP'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260325; submission_class_code=TYPE 1; brand_name=['LIFYORLI (COPACKAGED)']
FDA complete response letter Received an FDA complete response letter (NDA 219398, letter dated Dec 30, 2025; corrected letter issued Jan 28, 2026); 84 roles open. FDA NDA 219398 (Dec 30, 2025)
Evidence (1 event)
- Dec 30, 2025 · FDA NDA 219398
  CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Corcept Therapeutics Attention: Christopher Golis Vice President, Quality Assurance & Regulatory Affairs Redwood City, CA (street omitted) Dear Christopher Golis: Ple

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 9, 2026 Board tracked Radar started tracking this company’s job board (80 open jobs at last check). source ↗
Apr 30, 2026 Trial start Phase 1: Evaluating the Pharmacokinetics and Safety of Miricorilant source ↗
Mar 25, 2026 FDA FDA New drug/biologic (novel): LIFYORLI (COPACKAGED) (relacorilant) — NDA220641, Mar 25, 2026. Applicant at approval: Corcept Therapeutics Incorporated. source ↗
Jan 27, 2026 Trial start Phase 2: Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma source ↗
Jan 16, 2026 Trial start Phase 1/Phase 2: Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies source ↗
Sep 11, 2025 Trial start Phase 1: Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects source ↗
Aug 22, 2025 Trial start Phase 1: Evaluation of Miricorilant on Liver Fat in Patients With MASLD source ↗
Apr 11, 2025 Trial start Phase 2: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers source ↗
Mar 28, 2025 Trial start —: Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) source ↗
Oct 8, 2024 Trial start Phase 1: Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant source ↗
May 31, 2024 Trial start Phase 1: Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants source ↗
Oct 25, 2023 Trial start 2: A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) source ↗
Mar 31, 2023 Trial start Phase 4: Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) source ↗
Jan 24, 2023 Trial start Phase 1: Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant source ↗
Nov 15, 2022 Trial start Phase 2: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis source ↗
Jun 29, 2022 Trial start Phase 3: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer source ↗
May 25, 2022 Trial start Phase 1: Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants source ↗
Mar 4, 2022 Trial start —: A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) source ↗
Mar 3, 2022 Trial start Phase 1: Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant source ↗
Nov 23, 2021 Trial start Phase 1: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) source ↗
Aug 18, 2021 Trial start Phase 1: Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants source ↗
Aug 3, 2021 Trial start Phase 1: Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants source ↗
Jul 13, 2021 Trial start Phase 1: Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants source ↗
Jan 22, 2021 Trial start Phase 1: T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers source ↗
Nov 4, 2020 Trial start Phase 2: Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) source ↗

Showing 25 of 52 dated events.

Upcoming milestones

2026-10 (ESTIMATED) · Phase 2 · Dazucorilant in Patients With Amyotrophic Lateral Sclerosis · NCT05407324
Oct 30, 2026 (ESTIMATED) · Phase 1 · Evaluating the Pharmacokinetics and Safety of Miricorilant · NCT07553663
2026-12 (ESTIMATED) · Phase 2 · Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome · NCT03604198
2027-09 (ESTIMATED) · Phase 2 · Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · NCT07259317

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 80

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Senior Manager, SOX	Redwood City, California, United States	Oct 19, 2026	Oct 20, 2026	Not stated
Manager, Internal Events and Community	Redwood City, California, United States	Oct 16, 2026	Oct 17, 2026	Not stated
Associate I, Regulatory Affairs	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Associate Director, Regulatory Affairs	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Senior Manager, Development Systems	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Quality Systems GxP Training Specialist II	Redwood City, California, United States	Oct 15, 2026	Oct 16, 2026	Not stated
Clinical Sales Specialist (CS) - Pittsburgh North	Pittsburgh, Pennsylvania, United States	Oct 14, 2026	Oct 15, 2026	Mid
Human Resources Benefits & Operations Specialist II	Redwood City, California, United States	Oct 13, 2026	Oct 14, 2026	Mid
Clinical Sales Specialist (CS) - Montgomery, AL	Montgomery, Alabama, United States	Oct 13, 2026	Oct 14, 2026	Mid
Senior Director, Clinical Trial Patient Safety Lead	Redwood City, California, United States	Oct 8, 2026	Oct 9, 2026	Senior
Senior Director, Postmarketing Safety Operations Lead	Redwood City, California, United States	Oct 8, 2026	Oct 9, 2026	Senior
Senior Manager/Associate Director, Product Complaints and Investigations	Redwood City, California, United States	Oct 7, 2026	Oct 9, 2026	Senior
Senior Medical Director, Therapeutic Area Safety Physician - Endocrinology and Metabolic	Redwood City, California, United States	Oct 7, 2026	Oct 9, 2026	Senior
Senior Medical Director, Therapeutic Area Safety Physician - Oncology and Neurology	Redwood City, California, United States	Oct 7, 2026	Oct 9, 2026	Senior
Senior Manager, Oncology Commercial Learning and Development	Redwood City, California, United States	Oct 7, 2026	Oct 9, 2026	Senior
Manager, Pharmacokinetics	Redwood City, California, United States	Oct 2, 2026	Oct 9, 2026	Mid
Associate Director, Patient Safety & Pharmacovigilance Science	Redwood City, California, United States	Oct 2, 2026	Oct 9, 2026	Senior
Senior Director, Clinical Pharmacology	Redwood City, California, United States	Oct 2, 2026	Oct 9, 2026	Senior
Clinical Sales Specialist (CS) - Birmingham, AL	Birmingham, Alabama, United States	Oct 2, 2026	Oct 9, 2026	Mid
Senior Manager, Marketing (Peer to Peer Education)	United States	Oct 1, 2026	Oct 9, 2026	Senior
Senior Manager, Pipeline & Portfolio Market Planning	Redwood City, California, United States	Sep 30, 2026	Oct 9, 2026	Senior
Vice President, Biology	Redwood City, California, United States	Sep 23, 2026	Oct 9, 2026	Executive
Senior Associate, Regulatory Affairs	Redwood City, California, United States	Sep 23, 2026	Oct 9, 2026	Mid
Senior Specialist I, Patient Safety & Pharmacovigilance (Clinical Trial Safety Operations)	Redwood City, California, United States	Sep 22, 2026	Oct 9, 2026	Senior
Specialist I, Patient Safety and Pharmacovigilance Operations	Redwood City, California, United States	Sep 22, 2026	Oct 9, 2026	Entry
Associate Director, Pricing & Contracting Operations	United States	Sep 22, 2026	Oct 9, 2026	Senior
Clinical Sales Specialist (CS) - Hartford, CT	Hartford, Connecticut, United States	Sep 21, 2026	Oct 9, 2026	Mid
Associate Director, Patient Safety & Pharmacovigilance Compliance, Standards & Training	Redwood City, California, United States	Sep 21, 2026	Oct 9, 2026	Senior
Clinical Scientist/Sr. Clinical Scientist, Oncology	Redwood City, California, United States	Sep 18, 2026	Oct 9, 2026	Mid
Medical Director, Oncology	Redwood City, California, United States	Sep 18, 2026	Oct 9, 2026	Senior
Associate Director, Medical Writing	Redwood City, California, United States	Sep 15, 2026	Oct 9, 2026	Senior
Senior Manager, Digital & Omnichannel Marketing (Customer Experience)	United States	Sep 9, 2026	Oct 9, 2026	Senior
Senior Director, Legal & Compliance, OUS Regions	Munich, Bavaria, Germany	Sep 9, 2026	Oct 9, 2026	Senior
Director, Human Resources	Redwood City, California, United States	Sep 9, 2026	Oct 9, 2026	Senior
Senior Manager, Manufacturing	Redwood City, California, United States	Aug 27, 2026	Oct 9, 2026	Senior
Director, Medical Writing	Redwood City, California, United States	Aug 27, 2026	Oct 9, 2026	Senior
Associate Director, Clinical Supply Chain	Redwood City, California, United States	Aug 27, 2026	Oct 9, 2026	Senior
Senior Director, Revenue and Cost Accounting	Redwood City, California, United States	Aug 27, 2026	Oct 9, 2026	Senior
Clinical Sales Specialist (CS) - Louisville, KY	Louisville, Kentucky, United States	Aug 26, 2026	Oct 9, 2026	Mid
Clinical Sales Specialist (CS) - Old Bridge, NJ	Old Bridge, New Jersey	Aug 25, 2026	Oct 9, 2026	Mid
Senior Director, National Field Access, Endocrinology	United States	Aug 20, 2026	Oct 9, 2026	Senior
Field Reimbursement Manager (FRM), Endocrinology - Ohio	Columbus, Ohio, United States	Aug 18, 2026	Oct 9, 2026	Mid
Director, Oncology Clinical Affairs (MD)	United States	Aug 17, 2026	Oct 9, 2026	Senior
Medical Science Liaison, Oncology - Southern CA	Los Angeles, California, United States	Aug 13, 2026	Oct 9, 2026	Mid
Medical Science Liaison, Oncology - Southeast	Nashville, Tennessee, United States	Aug 13, 2026	Oct 9, 2026	Mid
Clinical Sales Specialist (CS) - Fresno, CA	Fresno, California, United States	Aug 12, 2026	Oct 9, 2026	Mid
Manager, Quality Operations	Redwood City, California, United States	Aug 10, 2026	Oct 9, 2026	Mid
Director, Key Account Managers	United States	Aug 7, 2026	Oct 9, 2026	Senior
Key Account Manager (KAM) - West	United States	Aug 7, 2026	Oct 9, 2026	Mid
Senior Regional Clinical Research Associate	Remote	Aug 5, 2026	Oct 9, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 80 jobs →

Clinical trials (lead sponsor) Showing 50 of 73

Record	Title	Phase	Status	Start	Primary completion
NCT03604198	Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome	Phase 2	Active, not recruiting	May 7, 2018	2026-12 (estimated)
NCT06947304	Evaluation of Miricorilant on Liver Fat in Patients With MASLD	Phase 1	Completed	Aug 22, 2025	Aug 13, 2026 (actual)
NCT06108219	A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)	2	Completed	Oct 25, 2023	Feb 13, 2026 (actual)
NCT05257408	Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer	Phase 3	Active, not recruiting	Jun 29, 2022	Mar 31, 2025 (actual)
NCT07259317	Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma	Phase 2	Recruiting	Jan 27, 2026	2027-09 (estimated)
NCT05407324	Dazucorilant in Patients With Amyotrophic Lateral Sclerosis	Phase 2	Active, not recruiting	Nov 15, 2022	2026-10 (estimated)
NCT07276373	Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies	Phase 1/Phase 2	Recruiting	Jan 16, 2026	2026-09 (estimated)
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	Phase 2	Recruiting	Apr 11, 2025	2026-08 (estimated)
NCT07553663	Evaluating the Pharmacokinetics and Safety of Miricorilant	Phase 1	Recruiting	Apr 30, 2026	Oct 30, 2026 (estimated)
NCT03437941	Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer	Phase 1/Phase 2	Terminated	Feb 20, 2018	Oct 13, 2021 (actual)
NCT07240116	Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects	Phase 1	Completed	Sep 11, 2025	Mar 3, 2026 (actual)
NCT06829537	Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)	Not listed	Completed	Mar 28, 2025	Dec 8, 2025 (actual)
NCT03776812	Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2	Completed	Apr 5, 2019	Mar 16, 2021 (actual)
NCT04308590	A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas	Phase 3	Completed	Jul 27, 2020	Sep 19, 2024 (actual)
NCT03697109	A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome	Phase 3	Completed	Nov 15, 2018	Apr 8, 2024 (actual)
NCT06495944	Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants	Phase 1	Completed	May 31, 2024	Aug 2, 2024 (actual)
NCT06928779	Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant	Phase 1	Completed	Oct 8, 2024	Dec 9, 2024 (actual)
NCT05553470	Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant	Phase 1	Completed	Mar 3, 2022	Sep 13, 2024 (actual)
NCT05772169	Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)	Phase 4	Completed	Mar 31, 2023	Nov 19, 2024 (actual)
NCT03818256	A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications	Phase 2	Completed	Dec 4, 2019	Jun 17, 2022 (actual)
NCT05117489	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)	Phase 1	Completed	Nov 23, 2021	Jan 29, 2024 (actual)
NCT05320146	A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)	Not listed	Completed	Mar 4, 2022	Jul 18, 2023 (actual)
NCT04524403	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)	Phase 2	Completed	Sep 9, 2020	Jul 29, 2022 (actual)
NCT04373265	Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)	Phase 1	Completed	Sep 30, 2020	Oct 17, 2023 (actual)
NCT04329949	Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Terminated	Jun 30, 2020	Aug 23, 2021 (actual)
NCT06094712	A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects	2	Completed	Apr 7, 2016	Apr 27, 2016 (actual)
NCT06094725	A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant	Phase 1	Completed	Jan 6, 2020	Dec 14, 2020 (actual)
NCT06094790	A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects	Phase 1	Completed	May 18, 2017	Nov 15, 2017 (actual)
NCT06094738	A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects	Phase 1	Completed	Sep 19, 2020	Nov 16, 2020 (actual)
NCT02663609	Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome	Not listed	Completed	2015-10	Dec 1, 2017 (actual)
NCT05712265	Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant	Phase 1	Completed	Jan 24, 2023	Feb 23, 2023 (actual)
NCT05003713	Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants	Phase 1	Completed	Aug 3, 2021	Feb 3, 2023 (actual)
NCT05347979	Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants	Phase 1	Completed	May 25, 2022	Jul 19, 2022 (actual)
NCT02762981	Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors	Phase 1/Phase 2	Completed	May 23, 2016	May 12, 2020 (actual)
NCT03823703	Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)	Phase 2	Terminated	Nov 4, 2020	Apr 5, 2021 (actual)
NCT04672512	Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants	Phase 1	Completed	Oct 23, 2020	Jan 17, 2022 (actual)
NCT00698022	A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers	Phase 1	Completed	2008-11	2009-02 (actual)
NCT04249323	Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants	Phase 1	Completed	Jan 27, 2020	Oct 15, 2020 (actual)
NCT04990310	Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants	Phase 1	Completed	Aug 18, 2021	Sep 20, 2021 (actual)
NCT04994743	Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants	Phase 1	Completed	Jul 13, 2021	Sep 30, 2021 (actual)
NCT04795479	T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers	Phase 1	Completed	Jan 22, 2021	May 17, 2021 (actual)
NCT04672499	Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants	Phase 1	Completed	Apr 27, 2020	Sep 7, 2020 (actual)
NCT03877562	The Effect of CORT118335 on Olanzapine-Induced Weight Gain	Phase 1	Completed	Apr 1, 2019	Mar 13, 2020 (actual)
NCT03512548	Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites	Phase 1	Completed	Apr 10, 2018	Jul 29, 2019 (actual)
NCT02804750	Study to Evaluate CORT125134 in Participants With Cushing's Syndrome	Phase 2	Completed	2016-06	2018-09 (actual)
NCT03067376	A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body	Phase 1	Completed	2016-08	2016-09 (actual)
NCT03508635	CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)	Phase 1	Completed	2014-09	2015-12 (actual)
NCT03379363	Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome	Not listed	Terminated	Sep 18, 2017	Feb 12, 2018 (actual)
NCT03878264	Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants	Phase 1	Completed	Aug 6, 2018	Mar 24, 2019 (actual)
NCT03315338	First-in-human Study in Healthy Subjects	Phase 1	Completed	Sep 15, 2017	Feb 22, 2019 (actual)

FDA records (last 2 years)

Mar 25, 2026 FDA New drug/biologic (novel): LIFYORLI (COPACKAGED) (relacorilant) — NDA220641, Mar 25, 2026. Applicant at approval: Corcept Therapeutics Incorporated. source ↗

Connect

See your connections at Corcept Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12